Almotriptan (Axert) vs Sumatriptan/naproxen sodium (Treximet)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Migraine
Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline
Almotriptan (Axert)
Rights held by Almirall and partners
NCT00257010 · Phase 3 · completed
This was a single-group, open-label study with 447 enrolled participants and no placebo or active comparator, so the reported pain-free headache counts cannot establish how much benefit was caused by almotriptan. The primary endpoint was a clinical migraine outcome, but no between-group comparison or statistical test was possible.
No aligned efficacy figure on record for this race.
Sumatriptan/naproxen sodium (Treximet)
Marketed by Azurity Pharmaceuticals and partners
NCT00488514 · Phase 3 · completed
The study was nonrandomized, open-label, and had no placebo or active comparator, although 656 adolescents were enrolled. Its posted primary safety endpoint found drug-related adverse events in 170 of 622 treated participants, but the uncontrolled design cannot establish how Treximet compares with no treatment or another migraine medicine.
No aligned efficacy figure on record for this race.
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Almotriptan (Axert): registry results are on file for Migraine, but their comparison mappings are not yet available.
Sumatriptan/naproxen sodium (Treximet): registry results are on file for Migraine, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Almotriptan (Axert)'s landscape · Sumatriptan/naproxen sodium (Treximet)'s landscape